A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
Severe eosinophilic asthma is associated with a heavy burden and impact on daily living in patients experiencing uncontrolled symptoms, exacerbations, and treatment side effects. This case study reports a 49-year-old woman who presented to the severe asthma center with uncontrolled severe asthma des...
Enregistré dans:
Auteurs principaux: | John Davison, Simon Doe |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Elsevier
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/80eca5f3ece644f09867e137f705a203 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
par: Caminati M, et autres
Publié: (2019) -
Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia
par: Kawabata H, et autres
Publié: (2021) -
Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
par: Haldar P
Publié: (2017) -
Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma
par: Angelantonio Maglio, et autres
Publié: (2021) -
Mepolizumab for severe eosinophilic asthma – A one-year real life Portuguese study
par: R Brás, et autres
Publié: (2021)